Prolonged Persistence of Lamivudine-resistant Mutant and Emergence of New Lamivudine-resistant Mutants Two Years After Lamivudine Withdrawal in HBsAg-positive Chronic Hepatitis Patient: A Case Report
暂无分享,去创建一个
[1] M. Nakanishi,et al. Long‐term follow‐up of chronic hepatitis B after the emergence of mutations in the hepatitis B virus polymerase region , 2005, Journal of viral hepatitis.
[2] S. Fan,et al. Clinical outcome and virologic profiles of severe hepatitis B exacerbation due to YMDD mutations. , 2003, Journal of hepatology.
[3] Y. Liaw,et al. The effect of lamivudine therapy in hepatic decompensation during acute exacerbation of chronic hepatitis B. , 2003, Journal of hepatology.
[4] D. Vassilopoulos,et al. Treatment of HBeAg-negative chronic hepatitis B. , 2003, Seminars in liver disease.
[5] Yoshiyuki Suzuki,et al. Long-term prognosis by lamivudine monotherapy for severe acute exacerbation in chronic hepatitis B infection: emergence of YMDD motif mutant and risk of breakthrough hepatitis -- an open-cohort study. , 2003, Journal of hepatology.
[6] M. Rizzetto,et al. Treatment of hepatitis B e antigen-negative chronic hepatitis B with lamivudine. , 2003, Journal of hepatology.
[7] C. Wai,et al. Fatal hepatitis B reactivation following discontinuation of nucleoside analogues for chronic hepatitis B , 2002, Gut.
[8] J.-H. Wang,et al. Fatal Hepatic Failure After Emergence of the Hepatitis B Virus Mutant During Lamivudine Therapy in a Patient with Liver Cirrhosis , 2002, Scandinavian journal of gastroenterology.
[9] J. Chi,et al. Fatal submassive hepatic necrosis associated with tyrosine-methionine-aspartate-aspartate-motif mutation of hepatitis B virus after long-term lamivudine therapy. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[10] J. R. Rebello Pinho,et al. Efficacy and tolerability of long-term therapy using high lamivudine doses for the treatment of chronic hepatitis B , 2001, Journal of Gastroenterology.
[11] T. Liang,et al. Molecular anatomy and pathophysiologic implications of drug resistance in hepatitis B virus infection. , 2001, Gastroenterology.
[12] Y. Liaw. Impact of YMDD mutations during lamivudine therapy in patients with chronic hepatitis B. , 2001, Antiviral chemistry & chemotherapy.
[13] A. Lok,et al. Evolution of hepatitis B virus polymerase gene mutations in hepatitis B e Antigen–negative patients receiving lamivudine therapy , 2000, Hepatology.
[14] R. D. de Man,et al. The sequential occurrence of viral mutations in a liver transplant recipient re-infected with hepatitis B: hepatitis B immune globulin escape, famciclovir non-response, followed by lamivudine resistance resulting in graft loss. , 1998, Journal of hepatology.
[15] K. Chayama,et al. Emergence and takeover of YMDD motif mutant hepatitis B virus during long‐term lamivudine therapy and re‐takeover by wild type after cessation of therapy , 1998, Hepatology.